

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Hoffmann-La Roche Inc.		12/11/2009	CORPORATION: NEW JERSEY

RECEIVING PARTY DATA

Name:	Validus Pharmaceuticals, Inc.
Street Address:	119 Cherry Hill Road
Internal Address:	Suite 310
City:	Parsippany
State/Country:	NEW JERSEY
Postal Code:	07054
Entity Type:	LIMITED LIABILITY COMPANY: DELAWARE

PROPERTY NUMBERS Total: 6

Property Type	Number	Word Mark
Registration Number:	1082213	ROCALTROL
Registration Number:	1122652	BUMEX
Registration Number:	3155034	EQUETRO
Registration Number:	0693079	MARPLAN
Registration Number:	3546060	MARPLAN
Serial Number:	77100210	VALIDUS PHARMACEUTICALS

CORRESPONDENCE DATA

Fax Number: (703)720-7399
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
 Phone: 703-720-7033
 Email: colleen.mcduffie@aporter.com
 Correspondent Name: Colleen Holcomb McDuffie
 Address Line 1: 1600 Tysons Boulevard
 Address Line 2: Suite 900

900150133

**TRADEMARK
 REEL: 004115 FRAME: 0526**

CH \$165.00 1082213

Address Line 4: McLean, VIRGINIA 22102

ATTORNEY DOCKET NUMBER:

01323.001

NAME OF SUBMITTER:

Colleen Holcomb McDuffie

Signature:

/Colleen Holcomb McDuffie/

Date:

12/16/2009

Total Attachments: 3

source=ReleaseSecInt#page1.tif

source=ReleaseSecInt#page2.tif

source=ReleaseSecInt#page3.tif

**TERMINATION AND RELEASE OF
SECURITY INTERESTS**

This TERMINATION AND RELEASE OF SECURITY INTERESTS, dated as of December 11, 2009, is made by HOFFMANN-LA ROCHE INC., a New Jersey corporation ("Roche"), in favor of VALIDUS PHARMACEUTICALS LLC, a Delaware corporation ("Validus").

WITNESSETH:

WHEREAS, Fontus Pharmaceuticals, Inc., a Delaware corporation ("Fontus"), and Roche are parties to a certain Secured Promissory Note dated as of June 16, 2008 (the "Original Note"); and

WHEREAS, contemporaneous with the Original Note, Fontus and Roche entered into an Intellectual Property Security Agreement (the "Original IP Security Agreement"); and

WHEREAS, the Original Note was superseded by that certain Amended and Restated Secured Promissory Note dated as of December 31, 2008, between Roche and Validus, Fontus's successor in interest (the "Note"), and the Original IP Security Agreement was superseded by an Amended and Restated Intellectual Property Security Agreement, dated as of December 31, 2008, between Roche and Validus (the "Amended IP Security Agreement"); and

WHEREAS, under the terms of the Note and the Amended IP Security Agreement, Validus granted and conveyed to Roche a continuing security interest (the "Security Interest") in Validus's right, title and interest in and to certain then-owned and any future-acquired IP Collateral (as defined in the Amended IP Security Agreement) including, without limitation, the intellectual property identified on Schedule A attached hereto;

WHEREAS, pursuant to that certain Forbearance Agreement and Release dated as of December 4, 2009, between Roche and Validus (the "Forbearance Agreement"), Roche has agreed to release its Security Interest in the IP Collateral.

NOW, THEREFORE, in consideration of the foregoing, Roche hereby releases its Security Interest in the IP Collateral, including but not limited to the intellectual property identified in Schedule A.

HOFFMANN-LA ROCHE INC.

By: _____

Name: MARK MACLEOD

Title: VICE PRESIDENT

Approved As To Form
LAW DEPT.

By: SA

Schedule A

U.S. Trademark Applications and Registrations

Mark	Registration No./ Application No.	Registration Date/ Filing Date
Rocaltrol®	Reg. No. 1,082,213	January 17, 1978
Bumex®	Reg. No. 1,122,652	July 24, 1979
Equetro	Reg. No. 3,155,034	October 10, 2006
Marplan	Reg. No. 693,079	December 16, 1960
Marplan Design	Reg. No. 3,546,060	December 16, 2008
Validus Pharmaceuticals	Application No. 77/100,210	filed February 6, 2007

U.S. and Canadian Patents and Patent Applications

Title	Patent No./Application Serial No.	Issue Date/Filing Date
Process for precursors to calcitriol and related compounds	Patent 5,182,393	Issued January 26, 1993
Process for precursors to calcitriol and related compounds	Patent 5,225,569	Issued July 6, 1993
Process for precursors to calcitriol and related compounds	Patent 5,352,781	Issued October 4, 1994
Methods for the treatment of bipolar disorder using Carbamazepine	Patent 6,977,253	Issued December 20, 2005
Methods for the treatment of bipolar disorder using Carbamazepine	Application 11/302,133 (Publication Number 2006/0094709)	Filed December 14, 2005

Pharmaceutical compositions for
treating or preventing migraines

Application
11/992,714

Methods for the treatment of bipolar
disorder using Carbamazepine

Canadian
Application
2452588

Filed December 8, 2003

U.S. Domain Name Registrations

fontuspharma.com

bumex.com -- domain name only

bumex.info - domain name only

bumex.us - domain name only

rocaltrol.us - domain name only

validuspharma.com

marplan.com -- domain name only

equetro.com -- domain name only